Search Results for: Research
Vitamin K deficiency is common among kidney transplant recipients (KTR) and likely contributes to progressive vascular calcification and stiffness. Vitamin K2’s proven cardiovascular support makes it a nutrient for consideration. MenaQ7 has been the source material for more than 22 published human clinical trials confirming safe and efficacious heart and bone benefits. Some of … Continue reading Vitamin K2’s Kidney Health Potential
Vitamin K deficiency is common among kidney transplant recipients (KTR) and likely contributes to progressive vascular calcification and stiffness. Vitamin K2’s proven cardiovascular support makes it a nutrient for consideration.
MenaQ7 has been the source material for more than 22 published human clinical trials confirming safe and efficacious heart and bone benefits. Some of those trials examined the positive impact of K2 supplementation in patients with compromised kidney health as those patients expressed intense calcification as a symptom of their condition.
According to the researchers of a new trial published in the American Journal of Transplantation, «in this randomized, double-blind, placebo-controlled clinical trial, vitamin K- supplementation did not alter serum calcification propensity, but ‘inhibited’ progression of arterial stiffness in KTR, suggesting that vitamin K may have vascular effects independent of serum calcification propensity. These results provide a basis for long-term intervention studies with vitamin K2-supplementation in KTR. »
Gnosis by Lesaffre finds these results promising, picking up on some of the important work that started with MenaQ7 Vitamin K2 as MK-7. Westenfeld et al. published a standout randomized controlled trial in 2013, that confirmed most hemodialysis patients have a functional vitamin K deficiency, and that K2 supplementation (as MenaQ7) induced a dose- and time-dependent decrease in circulating inactive Matrix Gla Protein (MGP) and Osteocalcin, the K-dependent proteins that support heart and bone health, respectively.
As March is National Kidney Month, we hope to shine a light on this important work showing the potential of a natural vitamin. And we will continue to drive discovery through scientific research.
MenaQ7 science has confirmed that Vitamin K2 simultaneously supports bone and heart health. But did you know that research also points to an important link between K2 and kidney health? We invite you to enjoy a new eBook that highlights Vitamin K2’s unique ability to help the body to properly utilize calcium, as well … Continue reading Vitamin K2 Health Benefits : New eBook
MenaQ7 science has confirmed that Vitamin K2 simultaneously supports bone and heart health. But did you know that research also points to an important link between K2 and kidney health?
We invite you to enjoy a new eBook that highlights Vitamin K2’s unique ability to help the body to properly utilize calcium, as well as detailing the groundbreaking science that shows MenaQ7 K2 supports bone health (in adults and children), and cardiovascular and kidney health (in adults).
Gnosis enriches its research advisory board to reflect existing clinical partnerships exploring new indications, advancing the potential for the K2 category. Gnosis by Lesaffre, the leading K2 supplier with the most and best clinically validated Vitamin K2 as MK-7, MenaQ7®, has enjoyed long-standing relationships with the world’s most renowned researchers. Today, the company announces … Continue reading Gnosis Expands Long-Standing Vitamin K2 Scientific Advisory Committee
Gnosis enriches its research advisory board to reflect existing clinical partnerships exploring new indications, advancing the potential for the K2 category.
Gnosis by Lesaffre, the leading K2 supplier with the most and best clinically validated Vitamin K2 as MK-7, MenaQ7®, has enjoyed long-standing relationships with the world’s most renowned researchers. Today, the company announces it is enhancing its Scientific Advisory Committee to highlight its commitment to exploring new indications while also identifying an expanding global presence of top thought leaders in biomedical research focused on Vitamin K2.
The Vitamin K2 Scientific Advisory Committee plays an integral role in program conceptualization, strategic development, and scientific advisory research regarding Vitamin K2. This group of esteemed, independent experts represents diverse geographic origins, helping Gnosis to identify specific population needs across the globe, offering a wide range of expertise and unique perspectives around K2. This, in turn, will return more robust opportunities for our finished product partners to create more impactful products for the market.
The Committee is chaired by the undisputed expert in Vitamin K2 research, Dr. Leon Schurgers, a Full Professor of Biochemistry of Vascular Calcification, Vice-Chair of Biochemistry at the Cardiovascular Research Institute Maastricht (CARIM), and chair of the stem cell research university Maastricht (SCRUM), Maastricht University (the Netherlands). He is also scientific advisor of the steering scientific board on the worldwide quality assurance plan for vitamin K detection, a member of the scientific advisory board of the Dutch Thrombosis Society, and author of more than 240 research papers in the international scientific press.
The Gnosis Vitamin K2 Scientific Advisory Committee was established based on the long-term, historical collaboration between Dr. Schurgers and Gnosis (previously NattoPharma). “No one has been a bigger proponent elucidating the benefits of vitamin K, and in particular K2 than Dr. Schurgers, as well as citing the absolute need for a K2-specific recommended daily intake (RDI),” says Jean-Francois Jeanne, Substantiation & Applications Team Manager. “Further, Gnosis has supported Research Teams worldwide, which has led to many new insights from clinical studies, including those identifying new clinical indications for K2, and combinations for K2, such as NOACs or Omega-3. This has ushered in an increased awareness of Vitamin K2’s potential grounded in science.”
“The collaboration between Gnosis and our research group at Maastricht University has led to many ground- breaking studies, including two PhD students that have defended their work at Maastricht University,” Schurgers says. “Further, Gnosis (previously NattoPharma) was a partner in EU Horizon 2020 innovative training programs, in which Maastricht University was beneficiary or coordinator. This clearly shows the scientific commitment of Gnosis.”
The Members of the Committee include:
• Hogne Vik, MD, PhD, MBA: A physician by education, Dr. Vik has served as a clinician, researcher, and Professor in Medicine at the University of Bergen, Norway. He is the author of more than 100 international research papers and has the last 25 years especially been interested in exploring health benefits associated with regular intake of vitamin K2 and omega-3 fatty acids. He has a successful scientific and commercial track record around these substances both within the pharmaceutical and dietary supplement industries. As previous CEO and Chief Medical Officer with NattoPharma ASA, he now serves as a medical and scientific advisor at Gnosis by Lesaffre.
• Katarzyna Maresz, PhD: Vitamin K2 scientific expert, Dr. Maresz is the former President of the International Science and Health Foundation, an independent research consortium dedicated to educating about the clinically validated benefits of nutrients, and the former Scientific Coordinator of the educational portal VitaminK2.org. She has published more than 30 scientific papers and is involved in Vitamin K2 clinical trials worldwide, cooperating with many research centers regarding the health effects and mechanism of action of Vitamin K2.
“I am honored to be invited into the Gnosis by Lesaffre Vitamin K2 Scientific Committee and look very much forward to continuing the scientific collaboration with Leon Schurgers and Katarzyna Maresz,” says Dr. Vik. “An assessment of available new biological data and documented clinical health benefits for vitamin K2 are, in my opinion, the best way to collect and communicate trustful information that will help people to understand why a regular intake of this vitamin is beneficial for health and quality of life.”
Gnosis by Lesaffre looks forward to announcing additional members in the immediate future. The group will be enlarged by those who have been collaborating with Gnosis for many years as well as new research partners to provide more visibility and ignite the passion for Vitamin K2.
“As the leader in the Vitamin K2 category, it is essential that we continue to drive the discovery of new indications and understanding, for benefit of our partners making the products that will shape a healthier global population,” says Marc Philouze, Gnosis by Lesaffre General Manager. “Our Scientific Advisory Committee has been at the forefront of that discovery, and their input will be essential to feed and continue in the delivery of the highest quality in science proposed by more than 70 Research & Application scientists working at Gnosis. It is our honor and obligation to enhance their potential for success.”
_______
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and well-being. The team draws on its focused research and application capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
About Lesaffre
A key global player in fermentation for more than a century, Lesaffre, with a 2.2 billion euro turnover, and established on all continents, counts 10,700 employees and more than 70 nationalities. On the strength of this experience and diversity, we work with customers, partners, and researchers to find ever more relevant answers to the needs of food, health, naturalness, and respect for our environment. Thus, every day, we explore and reveal the infinite potential of microorganisms. To nourish 10 billion people, in a healthy way, in 2050 by making the most of our planet’s resources is a major and unprecedented issue. We believe fermentation is one of the most promising answers to this challenge.
Lesaffre – Working together to better nourish and protect the planet.
Why is Vitamin K2 as MK-7 an essential nutrient for supporting cardiovascular health ? Check out this new video to find out. Gnosis by Lesaffre wants to create a healthier global population, and that starts with securing our cardiovascular health. MenaQ7® is the premium Vitamin K2 as MK-7 clinically proven to simultaneously support heart … Continue reading New MenaQ7® Heart Health Video
Why is Vitamin K2 as MK-7 an essential nutrient for supporting cardiovascular health ? Check out this new video to find out.
Gnosis by Lesaffre wants to create a healthier global population, and that starts with securing our cardiovascular health.
MenaQ7® is the premium Vitamin K2 as MK-7 clinically proven to simultaneously support heart and bone health by activating Vitamin K-dependent proteins already in the body. Where cardiovascular health is concerned, Matrix Gla Protein (MGP) is the most potent inhibitor of vascular calcification, but it needs adequate Vitamin K2 to activate it.
Learn more about MenaQ7® and the substantial research confirming its integral role in supporting heart health.
VETA Trial will evaluate the therapeutic effect of vitamins K2 and D3 paired with Empagliflozin on various diabetic and quality-of-life parameters. MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (8 Sept 2022) – A new study protocol1 has been published on ClinicalTrials.gov (NCT05417880) detailing a trial initiated by Gnosis by Lesaffre partner Scotmann Pharmaceuticals, … Continue reading NEW VITAMIN K2 CLINICAL TRIAL ANNOUNCED
VETA Trial will evaluate the therapeutic effect of vitamins K2 and D3 paired with Empagliflozin on various diabetic and quality-of-life parameters.
MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (8 Sept 2022) – A new study protocol1 has been published on ClinicalTrials.gov (NCT05417880) detailing a trial initiated by Gnosis by Lesaffre partner Scotmann Pharmaceuticals, Pakistan, who will execute a large-scale, multi-centered study to examine the impact of the combination of Empagliflozin, an oral anti-diabetic, with vitamins K2 and D3 on various diabetic parameters, including quality-of-life. Scotmann Pharmaceuticals, Pakistan uses Gnosis by Lesaffre’s vitamin K2 MK7 from natural fermentation, which has been validated in numerous clinical trials.
Globally, there were 437.9 million prevalent cases of Type 2 Diabetes in 2019, with an age-standarized point prevalence of 5,282.9 per 100,000 populations, which represents a 49% increase since 1990.2 The VETA Trial (Vitamin D, K2 plus Empagliflozin combination in Type Two Diabetes Mellitus) is a six-month prospective, randomized, controlled, open-label, multicenter trial conducted in collaboration with the University of Health Sciences Lahore (Pakistan) and the Pakistan Society of Internal Medicine. The study will enroll 340 participants, aged 40-60 years and having Type 2 Diabetes Mellitus (T2DM) for at least 10 years.
The participants will be allocated to either: the control group (continuing current oral anti-hyperglycemic other than SGLT2 inhibitors and no added D3 or K2 supplementation), the interventional groups receiving either 10mg Empagliflozin (a medication used together with diet and exercise to treat Type 2 diabetes; as VORETA tablets) or 10mg Empagliflozin plus the combination of 2,000 IUs of vitamin D3 and 100 mcg of Vitamin K2 as MK7 (as SunnyD PRO soft gel). The doses of both Empagliflozin tablets and the combination D3 + K2 soft gel will be taken once daily.
The main goals of the study are to:
- Explore the effects on hyperglycemic parameters (including HbA1c, FBS and RBS)
- Explore the effects on hyperlipidemic parameters (including HDL-C, LDL-C and Triglycerides)
- Assess the improvements in Diabetic Quality of Life parameters (DQol)
- Explore the effects on arterial calcification markers
“The idea is to follow the holistic approach guidelines for the management of T2DM,” says Dr. Syeda Saba Alsam, Head of Medical Affairs and Research with Scotmann Pharmaceuticals, Pakistan, noting that baseline screening of serum 25(OH)D3 levels would be done on all patients. “Since Vitamin D deficiency is highly prevalent in this cohort and a typical Pakistani diet lacks Vitamin K2, we are exploring the potential beneficial effects of these two micronutrients in Diabetic patients.”
“While treatment is crucial for diabetes, the proper nutrient intake is also important for this group of patients. Deficiency of vitamin D is globally recognized; however, the research suggests that vitamin D3 should be combined with vitamin K2 for synergistic impact. Further, it has been shown that vitamin K2 supplementation can effectively improve clinical features of diabetes,” says Sophie Legrain, Gnosis by Lesaffre Director of R&D, noting a study3 that showed vitamin K2 intake, specifically, produced a 7% reduction in T2DM risk with each 10mcg increment. “It is exciting to see our partner exploring the impact K2 and D3 could have for patients adding it to their therapy.”
References:
1https://clinicaltrials.gov/ct2/show/NCT05417880?term=vitamin+k2&draw=2
2 Safiri S et al. Prevalence, Deaths and Disabiity-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and its Attributable Risk Factors in 204 Countries and Territories, 1990-2-19: Results from the Global Buden of Disease Study 2019. Front. Endocrinol., 25 Feb 2022. 13:838027.
3 Beulens JW, et al. Dietary phylloquinone and menaquinones intakes and risk of type 2 diabetes. Diabetes Care. 2010;33:1699–705.
About Scotmann Pharmaceuticals, Pakistan
Scotmann is a pharmaceutical centre of excellence with a diversified portfolio of branded generics in biotech, cardiovascular, diabetes, gastroenterology, respiratory, inflammatory diseases, pain management, osteoporosis, psychiatry, and OTC segments. The company’s R&D is structured around partnerships with European Contract Research Organizations (CROs). These partnerships help Scotmann adhere to excellent manufacturing practices, ensuring that its products meet the highest international standards for safety and efficacy.
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and wellbeing. The team draws on its focused research and application capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com, +1 609-454-2992 x220
VIKIPEDIA Trial using 1mg MenaQ7® K2 as MK-7 was the centerpiece of a presentation at the 10th Annual Nephrology Symposium 2022 in Greece. MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (5 JANUARY 2023) – A presentation at the 10th Annual Nephrology Symposium 2022, an event organized by the Academy of Nephrology & Nephrology Clinic … Continue reading VITAMIN K2 IMPORTANCE FOR CARDIO HEALTH HIGHLIGHTED AT NEPHROLOGY SYMPOSIUM
VIKIPEDIA Trial using 1mg MenaQ7® K2 as MK-7 was the centerpiece of a presentation at the 10th Annual Nephrology Symposium 2022 in Greece.
MARCQ-EN-BAROEUL, FRANCE, AND EAST BRUNSWICK, NJ (5 JANUARY 2023) – A presentation at the 10th Annual Nephrology Symposium 2022, an event organized by the Academy of Nephrology & Nephrology Clinic of the University General Hospital of Larissa, Department of Medicine of the University of Thessaly, discussed the important role vitamin K2 plays in vascular calcification and the potential impact for chronic kidney disease patients. A core element of the presentation was a discussion of the current VIKIPEDIA Trial, which uses the highest dosage of MenaQ7Ò Vitamin K2 as MK-7 to date: 1 mg daily.
The Nephrology Symposium covers modern scientific developments in kidney diseases related to diagnosis, prevention, and treatment. According to event organizers, the main goal of the event is to contribute to more effective and correct treatment of kidney diseases. The program was attended by distinguished scientists from Greece and abroad with renowned clinical and research work in Nephrology and other fields of medicine.
One of those esteemed presenters was Stefanos Roumeliotis, MD, PhD, lead researcher of the multi-center, placebo-controlled, randomized, open-label intervention clinical trial “The Effect of Vitamin K2 Supplementation on Arterial stiffness and Cardiovascular Events in PEritonial DIAlysis (VIKIPEDIA)”. Dr. Roumeliotis and his colleagues at Aristotle University of Thessoloniki in Greece are studying the effect of K2 supplementation (through the normalization of dp-ucMGP) on arterial stiffness and the occurrence of cardiovascular events.
“Cardiovascular disease is the main cause of death in end-stage kidney disease patients undergoing maintenance dialysis, mainly due to accelerated vascular calcification. Having this in mind, it is crucial to investigate possible novel therapeutic choices to abrogate vascular calcification in these patients,” he explains. “Exogenous supplementation of vitamin K2 in dialysis patients has proven to be safe and well tolerated. This present study aims to elucidate whether increased vitamin K intake in peritoneal dialysis patients might be of cardiovascular benefit.
“VIKIPEDIA is the first study to assess whether a high dosage of menaquinone-7 could improve arterial stiffness, mortality, cardiovascular disease, 24-hour ambulatory blood pressure, and dialysis efficacy in patients with peritoneal dialysis,” Dr. Roumeliotis adds. “MenaQ7 was chosen to be used in the study because the compound showed its efficacy to improve vitamin K status in many clinical trials with kidney patients.”
The protocol for the 1.5-year study published in June 2021, and researchers will collaborate with renowned vitamin K researchers and Gnosis by Lesaffre research partner Maastricht University, the Netherlands.
“The implications of vitamin K2 being a part of this symposium are immeasurable,” says Sophie Legrain, Gnosis by Lesaffre Director of R&D. “It cannot be overstated the importance of every possible opportunity to advance industry, academic, and medical understanding of this essential nutrient. The VIKIPEDIA Trial using such a high dosage of our MenaQ7 K2 supports its high safety profile, and we are excited at the potential positive results can offer for an at-risk patient population.”
About Gnosis by Lesaffre
Gnosis by Lesaffre harnesses the power of microorganisms and biotransformation processes like fermentation to cultivate nutritional actives, probiotics, and nutritional and functional yeasts that benefit human health and well-being. The team draws on its focused research and application capabilities to collaborate with nutraceutical and pharmaceutical brands to develop game-changing products for their customers.
About Lesaffre
A key global player in fermentation for more than a century, Lesaffre, with a 2.2 billion euro turnover, and established on all continents, counts 10,700 employees and more than 70 nationalities. On the strength of this experience and diversity, we work with customers, partners, and researchers to find ever more relevant answers to the needs of food, health, naturalness, and respect for our environment. Thus, every day, we explore and reveal the infinite potential of microorganisms.
To nourish 10 billion people, in a healthy way, in 2050 by making the most of our planet’s resources is a major and unprecedented issue. We believe fermentation is one of the most promising answers to this challenge.
Lesaffre – Working together to better nourish and protect the planet.
For more information, please contact:
Kate Quackenbush, Communications Director, k.quackenbush@gnosis.lesaffre.com